New tests launched in March
New Tests
In March 2022, Mayo Clinic Laboratories announced eighteen new tests along with numerous reference value changes, obsolete tests, and algorithm changes.
The new tests that launched in March 2022 by Mayo Clinic Laboratories:
RLTE4 | Leukotriene E4, Random, Urine
This test is intended for an aid to evaluate patients suspected of having systemic mastocytosis using random urine collections.
TLTE4 | Leukotriene E4, 24 Hour, Urine
This test is intended for an aid to evaluate patients suspected of having systemic mastocytosis using 24-hour urine collections.
AFXN | Friedreich Ataxia, Repeat Expansion Analysis, Varies
This test is intended for molecular confirmation of clinically suspected Friedreich ataxia.
FHV8P | Herpesvirus 8 (HHV-8) DNA, Quantitative Real-Time PCR
This test is intended for real-Time Polymerase Chain Reaction, RT-PCR.
FJCQP | JC Polyoma Virus DNA, Quantitative Real-Time PCR, Plasma
This test is intended for real-Time Polymerase Chain Reaction (RT-PCR).
FHV6P | Herpesvirus 6 (HHV-6) DNA, Quantitative Real-Time PCR
This test is intended for real Time PCR.
FADNA | Adenovirus DNA, Quantitative Real-Time PCR
This test is intended for real-Time Polymerase Chain Reaction (RT-PCR).
FHV7P | Herpesvirus 7 (HHV-7) DNA, Quantitative Real-Time PCR
This test is intended for real-Time PCR.
EGFRS | EGFR Gene, Targeted Mutation Analysis, 51 Mutation Panel, Tumor
This test is intended for identifying non-small cell lung cancers that may respond to epidermal growth factor receptor-targeted therapies.
EGFRW | EGFR Targeted Mutation Analysis with ALK Reflex, Tumor
This test is intended for identifying non-small cell lung cancers that may benefit from treatment with epidermal growth factor receptor -targeted therapies or anaplastic lymphoma kinase inhibitors.
AMGEN | Mycoplasma genitalium, Transcription-Mediated Amplification, Varies
This test is intended for detection of Mycoplasma genitalium in cases of suspected infection.
This test is not intended for use in medico-legal applications.
AMISO | Amylase, Isoenzymes, Serum
This test is intended for ruling out salivary amylase as the cause of elevated serum amylase.
CHAGS | Trypanosoma cruzi Total Antibody, Enzyme-Linked Immunosorbent Assay, Serum
This test is intended for diagnosis of chronic Trypanosoma cruzi infection (Chagas disease).
CMPRE | Family Member Comparator Specimen for Exome Sequencing, Varies
This test is intended for submitting a biological family member’s specimen to be used as a comparator for affected patients (probands) undergoing whole exome sequencing.
WESDX | Whole Exome Sequencing for Hereditary Disorders , Varies
This test is intended for serving as a first-tier test to identify a molecular diagnosis in patients with suspected genetic disorders, which can allow for:
Serving as a second-tier test for patients in whom previous genetic testing was negative.
Providing a potentially cost-effective alternative to establishing a molecular diagnosis compared to performing multiple independent molecular assays.
RP | Respiratory Panel, PCR, Nasopharyngeal
This test is intended for rapid detection of respiratory infections caused by the following:
This test is not recommended as a test of cure.
RPB | Respiratory Panel, PCR, Varies
This test is intended for rapid detection of respiratory infections caused by the following:
This test is not recommended as a test of cure.
In addition to these tests, the department also announced several test changes. Click the links below to view test changes announced by Mayo Clinic Laboratories: